Jupiter Topco LLC Takes Position in Progyny, Inc. $PGNY

Jupiter Topco LLC bought a new position in Progyny, Inc. (NASDAQ:PGNY) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 450,412 shares of the company’s stock, valued at approximately $12,986,000. Jupiter Topco LLC owned about 0.59% of Progyny at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. BlackRock Inc. bought a new stake in shares of Progyny in the 2nd quarter worth approximately $334,426,000. Wellington Management Group LLP grew its holdings in shares of Progyny by 260.9% during the 4th quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock valued at $57,607,000 after purchasing an additional 1,621,688 shares during the last quarter. Fort Washington Investment Advisors Inc. OH grew its holdings in shares of Progyny by 46.9% during the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 2,693,393 shares of the company’s stock valued at $45,734,000 after purchasing an additional 859,289 shares during the last quarter. Loomis Sayles & Co. L P purchased a new position in Progyny in the 4th quarter worth $19,917,000. Finally, William Blair Investment Management LLC purchased a new position in Progyny in the 2nd quarter worth $16,807,000. 94.93% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently issued reports on PGNY shares. BTIG Research raised their price objective on Progyny from $30.00 to $40.00 and gave the company a “buy” rating in a research note on Friday, July 24th. Citizens Jmp boosted their target price on Progyny from $30.00 to $31.00 and gave the company a “market outperform” rating in a research note on Monday, May 11th. Citigroup restated an “outperform” rating on shares of Progyny in a report on Monday, May 11th. Weiss Ratings upgraded Progyny from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, August 13th. Finally, Wall Street Zen cut Progyny from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 25th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $33.91.

Progyny Trading Up 0.5%

Shares of NASDAQ:PGNY opened at $26.00 on Friday. The company has a 50-day moving average price of $29.08 and a 200-day moving average price of $23.63. The company has a market cap of $1.99 billion, a price-to-earnings ratio of 28.26, a price-to-earnings-growth ratio of 1.79 and a beta of 1.01. Progyny, Inc. has a 12 month low of $16.10 and a 12 month high of $33.06.

Progyny (NASDAQ:PGNY) last posted its earnings results on Thursday, August 6th. The company reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.33 by $0.22. Progyny had a return on equity of 15.98% and a net margin of 6.00%.The company had revenue of $350.51 million for the quarter, compared to analysts’ expectations of $349.05 million. During the same period last year, the firm earned $0.19 earnings per share. Progyny’s quarterly revenue was up 5.3% on a year-over-year basis. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. As a group, research analysts forecast that Progyny, Inc. will post 1.25 EPS for the current fiscal year.

Progyny announced that its board has approved a stock buyback program on Tuesday, May 26th that authorizes the company to repurchase $200.00 million in shares. This repurchase authorization authorizes the company to purchase up to 10.3% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s management believes its stock is undervalued.

Insiders Place Their Bets

In related news, CFO Mark S. Livingston sold 2,517 shares of the firm’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $25.50, for a total value of $64,183.50. Following the completion of the sale, the chief financial officer owned 74,688 shares of the company’s stock, valued at $1,904,544. This trade represents a 3.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Cheryl Scott sold 7,439 shares of Progyny stock in a transaction on Monday, June 1st. The shares were sold at an average price of $26.39, for a total transaction of $196,315.21. Following the completion of the sale, the director owned 19,772 shares in the company, valued at approximately $521,783.08. This trade represents a 27.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 13,563 shares of company stock valued at $351,968 in the last 90 days. 9.90% of the stock is owned by corporate insiders.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.